

ANSWERING REVIEWERS

July 11, 2014



Dear Reviewers,

Title: New targeted therapies for breast cancer: how is Breast Cancer treated?

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

Suggestion 1: Recommend to condense the paper and to characterize the breast cancer treatment based on the current breast cancer molecular classification (Luminal type, Her2 type, triple-negative/basal like) 2.

Answer: The World Journal of Clinical Case has no restrictions on length and Figures.

Suggestion 2: Currently triple negative (TN) breast cancer is therapeutically challenging due to lack of molecular targets. Many related studies are under investigation. Rb/p16 pathway abnormality and p53 mutation play roles in poor prognosis of TN cancer, which may contribute to the development of targeted therapy for TN cancer patients. Two recently published articles demonstrated expression of p16 and p53 in TN breast cancer and discussed the two biomarkers' potential role for being a target candidate. This manuscript did not include them. #Ki-67 Expression is Increased in p16 Expressing Triple-negative Breast Carcinoma and Correlates with p16 only in p53-negative Tumors. Human Pathology. 2014 Apr;45(4):802-9 #Roles of p53 and p16 in Triple-negative Breast Cancer, Breast Cancer Management (Future Medicine). 2013;2:537-544.

Answer: I have added both papers in the manuscript (see Page 10) (82, 83).

Suggestion 3: Page 15, ref #158 needs to be updated. The updated Her2 guidelines published in 2013 is as follows: Arch Pathol Lab Med. Doi:10.5858/arpa.2013-0953-SA. The Her2 related statement on the page 15 needs to be revised accordingly.

Answer: I have updated Page 15, ref #158.

Suggestion 4: In the first sentence of the second paragraph of "I-Introduction", there is a minor grammar error: "The breast microenvironment consists of"

Answer: I have added s to consist

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Clinical Case*

Sincerely yours,



Dr. Armel Hervé NWABO KAMDJE, Ph.D

Senior Lecturer/Assistant Professor, University of Ngaoundere-Cameroon

Department of Biomedical Sciences

Editorial board member of the International Blood Research and Review

Editorial board member of Frontiers in Cellular Biochemistry

Editorial board member of the Journal of Blood and Lymph

<http://www.sciencedomain.org/editorial-board-members.php?id=28>

<http://www.omicsgroup.org/journals/editorialboardJBL.php>

Tel. +23777463063/+23790190421/+14389322303

E-mail: armel.nwabo@gmail.com / kamdjewa@yahoo.fr / ah.nwabo@univ-ndere.cm

<http://scholar.google.ca/citations?hl=en&user=JYInD5wAAAAJ>

